Tomohiro Tanaka

3.8k total citations · 2 hit papers
88 papers, 2.2k citations indexed

About

Tomohiro Tanaka is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Tomohiro Tanaka has authored 88 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Oncology, 43 papers in Immunology and 20 papers in Molecular Biology. Recurrent topics in Tomohiro Tanaka's work include Chemokine receptors and signaling (34 papers), Immunotherapy and Immune Responses (33 papers) and T-cell and B-cell Immunology (18 papers). Tomohiro Tanaka is often cited by papers focused on Chemokine receptors and signaling (34 papers), Immunotherapy and Immune Responses (33 papers) and T-cell and B-cell Immunology (18 papers). Tomohiro Tanaka collaborates with scholars based in Japan, United States and Singapore. Tomohiro Tanaka's co-authors include Tomohide Tamura, Kazuhiko Nakagawa, Makoto Nishio, Hirokazu Tamamura, Nobuyuki Yamamoto, Toyoaki Hida, Takashi Seto, Hiroshige Yoshioka, Yuichiro Ohe and Wataru Nomura and has published in prestigious journals such as Journal of the American Chemical Society, Angewandte Chemie International Edition and Journal of Clinical Oncology.

In The Last Decade

Tomohiro Tanaka

84 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

2014 538 citations Tomohiro Tanaka et al. profile →
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

2013 449 citations Yuichiro Ohe, Tomohiro Tanaka et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tomohiro Tanaka Japan	21	1.5k	1.2k	754	386	179	88	2.2k
Collin M. Blakely United States	21	808 0.6×	772 0.7×	800 1.1×	302 0.8×	130 0.7×	75	2.1k
Dagmar Hess Switzerland	20	897 0.6×	368 0.3×	880 1.2×	243 0.6×	126 0.7×	61	1.7k
C. Martin Curtis United States	15	865 0.6×	624 0.5×	952 1.3×	106 0.3×	262 1.5×	18	1.6k
Delphine Loirat France	29	2.1k 1.5×	1.0k 0.9×	502 0.7×	524 1.4×	112 0.6×	109	2.9k
David R. Stover United States	23	1.1k 0.8×	372 0.3×	1.4k 1.9×	401 1.0×	139 0.8×	47	3.0k
Angela Märten Germany	29	2.3k 1.6×	1.5k 1.2×	926 1.2×	1.1k 3.0×	88 0.5×	133	3.4k
Jeffrey J. Wallin United States	28	1.2k 0.8×	483 0.4×	829 1.1×	1.1k 2.9×	252 1.4×	60	2.8k
Ron Yu United States	14	949 0.7×	344 0.3×	724 1.0×	109 0.3×	83 0.5×	32	1.7k
Maarten L. Janmaat Netherlands	17	1.3k 0.9×	525 0.4×	1.0k 1.4×	567 1.5×	180 1.0×	28	2.4k
Amanda L. Christie United States	21	1.0k 0.7×	244 0.2×	1.6k 2.1×	275 0.7×	234 1.3×	34	2.4k

Countries citing papers authored by Tomohiro Tanaka

Since Specialization

Citations

This map shows the geographic impact of Tomohiro Tanaka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomohiro Tanaka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomohiro Tanaka more than expected).

Fields of papers citing papers by Tomohiro Tanaka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomohiro Tanaka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomohiro Tanaka. The network helps show where Tomohiro Tanaka may publish in the future.

Co-authorship network of co-authors of Tomohiro Tanaka

This figure shows the co-authorship network connecting the top 25 collaborators of Tomohiro Tanaka. A scholar is included among the top collaborators of Tomohiro Tanaka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomohiro Tanaka. Tomohiro Tanaka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tanaka, Tomohiro, Yasushi Goto, Ken Masuda, et al.. (2024). The remarkable antitumor efficacy of corticosteroid treatment in patients with refractory thymomas. Respiratory Investigation. 62(5). 766–772. 1 indexed citations

Tanaka, Tomohiro, et al.. (2024). Cx ₃ Mab-4: A Novel Anti-Mouse CXCR3 Monoclonal Antibody for Flow Cytometry. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 43(3). 90–95. 3 indexed citations

Li, Guanjie, et al.. (2024). Cx ₁ Mab-1: A Novel Anti-mouse CXCR1 Monoclonal Antibody for Flow Cytometry. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 43(2). 59–66. 1 indexed citations

Tanaka, Tomohiro, Yasushi Goto, Masafumi Horie, et al.. (2023). Whole Exome Sequencing of Thymoma Patients Exhibiting Exceptional Responses to Pemetrexed Monotherapy. Cancers. 15(16). 4018–4018. 2 indexed citations

Tanaka, Tomohiro, Hiroyuki Suzuki, Teizo Asano, et al.. (2023). Epitope Mapping of the Novel Anti-Human CCR9 Monoclonal Antibody (C ₉ Mab-11) by 2 × Alanine Scanning. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 42(2). 73–76. 2 indexed citations

Asano, Teizo, et al.. (2023). Determination of the Binding Epitope of an Anti-Mouse CCR9 Monoclonal Antibody (C9Mab-24) Using the 1× Alanine and 2× Alanine-Substitution Method. Antibodies. 12(1). 11–11. 1 indexed citations

Tanaka, Tomohiro, Hiroyuki Suzuki, Kazuyuki Uchida, et al.. (2023). PMab-301: An Anti-Giraffe Podoplanin Monoclonal Antibody for Immunohistochemistry. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 42(6). 209–215.

Tanaka, Tomohiro, Hiroyuki Suzuki, Teizo Asano, et al.. (2022). Epitope Mapping of an Anti-Mouse CXCR6 Monoclonal Antibody (Cx ₆ Mab-1) Using the 2 × Alanine Scanning Method. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 41(5). 275–278. 8 indexed citations

Suzuki, Hiroyuki, et al.. (2022). Epitope Mapping of an Anti-Chinese/Golden Hamster Podoplanin Monoclonal Antibody. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 41(3). 163–169. 1 indexed citations

10.

Tanaka, Tomohiro, Tatsuya Yoshida, Ken Masuda, et al.. (2022). Prognostic role of modified Glasgow Prognostic score in elderly non-small cell lung cancer patients treated with anti-PD-1 antibodies. Respiratory Investigation. 61(1). 74–81. 13 indexed citations

11.

Tanaka, Tomohiro, Hiroyuki Suzuki, Teizo Asano, et al.. (2022). Epitope Mapping Using the Cell-Based 2 × Alanine Substitution Method About the Anti-mouse CXCR6 Monoclonal Antibody, Cx ₆ Mab-1. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 42(1). 22–26. 3 indexed citations

12.

Tanaka, Tomohiro, Guanjie Li, Teizo Asano, et al.. (2022). Epitope Mapping of the Anti-Human CCR2 Monoclonal Antibody C ₂ Mab-9. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 41(3). 150–156. 3 indexed citations

13.

Asano, Teizo, Hiroyuki Suzuki, Tomohiro Tanaka, et al.. (2022). Establishment of a Sensitive Monoclonal Antibody Against Mouse CCR9 (C ₉ Mab-24) for Flow Cytometry. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 42(1). 15–21. 4 indexed citations

14.

Suzuki, Hiroyuki, et al.. (2022). Development of a Monoclonal Antibody PMab-292 Against Ferret Podoplanin. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 41(2). 101–109. 10 indexed citations

15.

Saito, Masaki, Guanjie Li, Teizo Asano, et al.. (2022). C ₃ Mab-2: An Anti-Mouse CCR3 Monoclonal Antibody for Immunocytochemistry. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 41(1). 45–49. 6 indexed citations

16.

Li, Guanjie, Hiroyuki Suzuki, Junko Takei, et al.. (2022). Immunohistochemical Analysis Using Monoclonal Antibody PMab-269 Against Steller Sea Lion Podoplanin. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 41(1). 39–44. 1 indexed citations

17.

Nanamiya, Ren, Junko Takei, Teizo Asano, et al.. (2021). Development of Anti-Human CC Chemokine Receptor 9 Monoclonal Antibodies for Flow Cytometry. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 40(3). 101–106. 37 indexed citations

18.

Hosono, Hideki, Teizo Asano, Junko Takei, et al.. (2021). Development of an Anti-Elephant Podoplanin Monoclonal Antibody PMab-265 for Flow Cytometry. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 40(3). 141–145. 12 indexed citations

19.

Kawasaki, Yuki, Chul Min Park, Tomohiro Tanaka, et al.. (2016). Feedback control of ErbB2 via ERK-mediated phosphorylation of a conserved threonine in the juxtamembrane domain. Scientific Reports. 6(1). 31502–31502. 21 indexed citations

20.

Sato, Ko, Satoshi Watanabe, Satoshi Shoji, et al.. (2016). Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors. BMC Cancer. 16(1). 222–222. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact